Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eladynos

- PMLiVE

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation

- PMLiVE

Boehringer/Lilly’s empagliflozin among CHMP recommendations

If approved it will be marketed as Jardiance

- PMLiVE

Amgen cholesterol antibody shines in rare disease trial

Evolocumab passes late-stage study

EU flag

European Commission sets out HIV/Aids action plan

Says two-year programme proves HIV/Aids remains an EU health policy priority

- PMLiVE

Pharma’s winners and losers in 2013

Roche, Johnson & Johnson and Amgen rise up the PMLiVE Top Pharma List rankings

Bristol-Myers Squibb (BMS) building

BMS’ novel HIV drug clears phase II trial

Entry inhibitor BMS-660368 moves closer to first-in-class approval

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

GSK’s Anoro backed in Europe for COPD

CHMP recommendation set to expand pharma company’s respiratory portfolio

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

- PMLiVE

A new option for people with HIV

ViiV Healthcare's dolutegravir could capture a significant share of the HIV market and may have blockbuster potential

- PMLiVE

Mylan to sell Gilead’s medicines in India

Includes HIV treatments Viread, Truvada and Stribild

- PMLiVE

EMA brings transparency to its committee proceedings

Publishes meeting minutes of CHMP and two other advisory groups

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links